SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-21-013517
Filing Date
2021-12-23
Accepted
2021-12-23 16:33:19
Documents
14
Period of Report
2021-12-22
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT gtbp_8k.htm   iXBRL 8-K 19021
  Complete submission text file 0001654954-21-013517.txt   142100

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA gtbp-20211222.xsd EX-101.SCH 5616
3 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE gtbp-20211222_cal.xml EX-101.CAL 904
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE gtbp-20211222_def.xml EX-101.DEF 2111
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE gtbp-20211222_lab.xml EX-101.LAB 14803
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gtbp-20211222_pre.xml EX-101.PRE 9425
8 EXTRACTED XBRL INSTANCE DOCUMENT gtbp_8k_htm.xml XML 3597
Mailing Address 9350 WILSHIRE BLVD. SUITE 203 BEVERLY HILLS CA 90212
Business Address 9350 WILSHIRE BLVD. SUITE 203 BEVERLY HILLS CA 90212 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

IRS No.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40023 | Film No.: 211517572
SIC: 2834 Pharmaceutical Preparations